Short answer
STANDARD BIOTOOLS INC. (LAB) filed its Q3 2025 10-Q quarterly report on Nov 4, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $20M (down 56.5% year over year) with net income of −$35M.
Q3 2025 key financials · XBRL
- Revenue
- $20M
- −56.5% YoY · +1544.4% QoQ
- Net income
- −$35M
- −28.8% YoY · −3.7% QoQ
- Operating margin
- -168.5%
- Gross margin
- 48.5%
- EPS (diluted)
- −$0.09
- −28.6% YoY · +0.0% QoQ
Source: XBRL data from the STANDARD BIOTOOLS INC. (LAB) Q3 2025 10-Q on SEC EDGAR. USD.
STANDARD BIOTOOLS INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $19.552M, down 11% YoY from $22.086M, driven by consumables decline
- Gross margin 48.5% vs 54.9% YoY; net loss $34.687M vs $26.938M
- Worst product line consumables revenue $8.705M, down 17% YoY from $10.508M
- Cash, equivalents, and investments $214.4M vs $292.9M at December 31, 2024
- Near-term headwinds: budget limitations, constrained funding, delayed purchases, and slower deal closures
Risk Factors
- No risk-factors section provided in submitted text
- Share-repurchase liquidity exposure: $40.5 million used of $50.0 million authorization
- Capital-allocation risk: repurchases funded by cash on hand through March 1, 2026
- Insider-trading compliance risk: no officer or director trading arrangements adopted, modified, or terminated during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other STANDARD BIOTOOLS INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.